The USFDA has recently approved a chairside blood test that can detect early stages of breast cancer. The test has been granted ‘Breakthrough Designation.’ The blood test was developed in India; it uses proprietary technology to detect circulating tumor cells and clusters specific to breast cancer. Study specifics A clinical trial was conducted and validated on 20,000 women above the age of 40 years.
The process required withdrawing 5 ml of blood. Highlights for the Breakthrough Designation An accuracy level of over 99% in the detection of stage 0 (ductal carcinoma in situ) and stage I of breast cancers No false positives No radiation exposure No discomfort of mammography Basic requirement – minimal blood withdrawal only The test could be performed at home or the office The approval and authorization of this test globally can revolutionize life expectancy in women with breast cancer.…
